Sunvozertinib | CAS# 2370013-12-8 | EGFR inhibitor

MedKoo Cat#: 414724 | Name: Sunvozertinib

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sunvozertinib, also known as DZD9008, is an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor. Sunvozertinib shows activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily.

Chemical Structure

Sunvozertinib

CAS#2370013-12-8 (R-isomer)

Theoretical Analysis

MedKoo Cat#: 414724

Name: Sunvozertinib

CAS#: 2370013-12-8 (R-isomer)

Chemical Formula: C29H35ClFN7O3

Exact Mass: 583.2474

Molecular Weight: 584.09

Elemental Analysis: C, 59.63; H, 6.04; Cl, 6.07; F, 3.25; N, 16.79; O, 8.22

Price and Availability

Size	Price	Availability
25mg	USD 150.00	2 Weeks
50mg	USD 250.00	2 Weeks
100mg	USD 450.00	2 Weeks
200mg	USD 750.00	2 Weeks
500mg	USD 1,650.00	2 Weeks
1g	USD 2,950.00	2 Weeks
2g	USD 5,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

2370013-49-1 (S-isomer) 2370013-12-8 (R-isomer)

Synonym

Sunvozertinib; DZD 9008; (DZD-9008; DZD9008;

IUPAC/Chemical Name

N-{5-({4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl}amino)-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamide

InChi Key

BTMKEDDEMKKSEF-QGZVFWFLSA-N

InChi Code

InChI=1S/C29H35ClFN7O3/c1-7-27(39)34-22-14-23(25(41-6)15-24(22)38-11-9-17(16-38)37(4)5)35-28-32-10-8-26(36-28)33-21-13-19(30)20(31)12-18(21)29(2,3)40/h7-8,10,12-15,17,40H,1,9,11,16H2,2-6H3,(H,34,39)(H2,32,33,35,36)/t17-/m1/s1

SMILES Code

C=CC(NC1=CC(NC2=NC=CC(NC3=CC(Cl)=C(F)C=C3C(C)(O)C)=N2)=C(OC)C=C1N4C[C@H](N(C)C)CC4)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 584.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shi Y, Xu Y, Wang M. Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation. BMC Cancer. 2024 Aug 23;24(1):1043. doi: 10.1186/s12885-024-12797-3. PMID: 39179992; PMCID: PMC11342509. 2: Ding K, Peng Z, Liu D, Xu Y. Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation. J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y. PMID: 39143613; PMCID: PMC11323653. 3: Luan T, Lin X, Xie X, Yang G, Wang S, Hao J, Zhou C. First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma. Anticancer Drugs. 2024 Sep 1;35(8):757-760. doi: 10.1097/CAD.0000000000001628. Epub 2024 Jun 26. PMID: 38924456; PMCID: PMC11305621. 4: Seo D, Lim JH. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non- Small-Cell Lung Cancer. Int J Mol Sci. 2024 May 29;25(11):5917. doi: 10.3390/ijms25115917. PMID: 38892105; PMCID: PMC11172945. 5: Park J, Lee B, Song JY, Sung M, Kwon MJ, Kim CR, Lee S, Shin YK, Choi YL. Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine. Pathology. 2024 Aug;56(5):653-661. doi: 10.1016/j.pathol.2024.02.012. Epub 2024 May 6. PMID: 38811262. 6: Kobayashi IS, Shaffer W, Viray H, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB. The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2023 Nov 27;5(1):100614. doi: 10.1016/j.jtocrr.2023.100614. PMID: 38229766; PMCID: PMC10788275. 7: Wang M, Fan Y, Sun M, Wang Y, Zhao Y, Jin B, Hu Y, Han Z, Song X, Liu A, Tang K, Ding C, Liang L, Wu L, Gao J, Wang J, Cheng Y, Zhou J, He Y, Dong X, Yao Y, Yu Y, Wang H, Sun S, Huang J, Fang J, Li W, Wang L, Ren X, Zhou C, Hu Y, Zhao D, Yang R, Xu F, Huang Y, Pan Y, Cui J, Xu Y, Yang Z, Shi Y. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non- small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single- arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2024 Mar;12(3):217-224. doi: 10.1016/S2213-2600(23)00379-X. Epub 2023 Dec 12. PMID: 38101437. 8: Hayashi H. Sunvozertinib: the next candidate of TKI for NSCLC. Lancet Respir Med. 2024 Mar;12(3):185-186. doi: 10.1016/S2213-2600(23)00419-8. Epub 2023 Dec 12. PMID: 38101435. 9: Dhillon S. Sunvozertinib: First Approval. Drugs. 2023 Nov;83(17):1629-1634. doi: 10.1007/s40265-023-01959-5. PMID: 37962831. 10: Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care; Chinese Association for Clinical Oncologists. [China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)]. Zhonghua Yi Xue Za Zhi. 2023 Oct 31;103(40):3160-3173. Chinese. doi: 10.3760/cma.j.cn112137-20230505-00725. PMID: 37879869. 11: Hamada A, Suda K, Nishino M, Obata K, Oiki H, Fukami T, Fukuda S, Fujino T, Ohara S, Koga T, Chiba M, Shimoji M, Ito M, Takemoto T, Soh J, Tsutani Y, Mitsudomi T. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion. J Thorac Oncol. 2024 Jan;19(1):71-79. doi: 10.1016/j.jtho.2023.08.029. Epub 2023 Sep 2. PMID: 37666482. 12: Sentana-Lledo D, Academia E, Viray H, Rangachari D, Kobayashi SS, VanderLaan PA, Costa DB. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates. Transl Lung Cancer Res. 2023 Jul 31;12(7):1590-1610. doi: 10.21037/tlcr-23-98. Epub 2023 Jul 5. PMID: 37577308; PMCID: PMC10413034. 13: Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, Cheng Y, Jiang L, Brungs D, Bazhenova L, Lee CK, Gao B, Xu Y, Hsu WH, Zheng L, Jänne PA. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Cancer Discov. 2022 Jul 6;12(7):1676-1689. doi: 10.1158/2159-8290.CD-21-1615. PMID: 35404393; PMCID: PMC9262839.